Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/s41571-019-0192-6.pdf
Reference1 articles.
1. Herrlinger, U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet 393, 678–688 (2019)
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development of novel lysosome-related signatures and their potential target drugs based on bulk RNA-seq and scRNA-seq for diabetic foot ulcers;Human Genomics;2024-06-11
2. Establishment and characteristics of GWH04, a new primary human glioblastoma cell line;International Journal of Oncology;2022-09-26
3. Glioblastoma, from disease understanding towards optimal cell-based in vitro models;Cellular Oncology;2022-06-28
4. METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner;Frontiers in Oncology;2021-07-15
5. Upregulation of Piezo1 Is a Novel Prognostic Indicator in Glioma Patients;Cancer Management and Research;2020-05
Upregulation of Piezo1 Is a Novel Prognostic Indicator in Glioma Patients
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3